Saurashtra University Re – Accredited Grade ‘B’ by NAAC (CGPA 2.93)
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Diazoles: Promising and Versatile Class to Design Anti Microbial Agents
International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 0974-4304 Vol.5, No.2, pp 568-576, April-June 2013 Diazoles: Promising and Versatile Class To Design Anti Microbial Agents Kaushik Kapuriya1*, Ashok. Ganure2, Abhishek Pall1 1Siksha o’ Anusandhan University, Bhubaneshwar, Orissa, India 2K. J. College of pharmacy, Vadasama, Mehasana, Gujarat, India *Corres. author: [email protected] Tel.: +0281-2459438 Mob. 07600028116 Abstract: Diazoles is highly privileged structure which includes imidazole, benzimidazole, pyrazole and oxadiazole and its derivatives exhibit wide range of pharmacological activity. Various biologically active synthetic compounds have five-membered nitrogen-containing heterocyclic ring in their structures. Given review shows diazoles structural frameworks can be described as privileged structures to design novel antimicrobial agents. Resistant to number of antimicrobial agent among a variety of clinically significant species of bacteria is becoming increasingly important global problem. This review has basic information about general synthesis and antimicrobial activity work for development in medicinal chemistry field. Key words: Diazole; Imidazole; Benzimidazole; Pyrazole; Oxadiazole; Antimicrobial activity. 1. Introduction Diazole refers to either one of a pair of isomeric chemical compounds with molecular formula C3H4N2, having a five-membered ring consisting of three carbon atoms and two nitrogen atoms. Five membered and two nitrogen heteroatom containing heterocyclic compounds like Imidazole, Benzimidazole, Pyrazole, Oxadiazole, and Thiadiazole possess varieties of biological activity. These entire compounds collectively known as diazole. Various biologically active synthetic compounds have five-membered nitrogen-containing heterocyclic ring in their structures [1-4]. Structural frameworks have been described as privileged structures and in particular, N containing polycyclic structures have been reported to be associated with a wide range of biological activity. -
|||||||||||||III US005202354A United States Patent (19) (11) Patent Number: 5,202,354 Matsuoka Et Al
|||||||||||||III US005202354A United States Patent (19) (11) Patent Number: 5,202,354 Matsuoka et al. 45) Date of Patent: Apr. 13, 1993 (54) COMPOSITION AND METHOD FOR 4,528,295 7/1985 Tabakoff .......... ... 514/562 X REDUCING ACETALDEHYDE TOXCTY 4,593,020 6/1986 Guinot ................................ 514/811 (75) Inventors: Masayoshi Matsuoka, Habikino; Go OTHER PUBLICATIONS Kito, Yao, both of Japan Sprince et al., Agents and Actions, vol. 5/2 (1975), pp. 73) Assignee: Takeda Chemical Industries, Ltd., 164-173. Osaka, Japan Primary Examiner-Arthur C. Prescott (21) Appl. No.: 839,265 Attorney, Agent, or Firn-Wenderoth, Lind & Ponack 22) Filed: Feb. 21, 1992 (57) ABSTRACT A novel composition and method are disclosed for re Related U.S. Application Data ducing acetaldehyde toxicity, especially for preventing (63) Continuation of Ser. No. 13,443, Feb. 10, 1987, aban and relieving hangover symptoms in humans. The com doned. position comprises (a) a compound of the formula: (30) Foreign Application Priority Data Feb. 18, 1986 JP Japan .................................. 61-34494 51) Int: C.5 ..................... A01N 37/00; A01N 43/08 52 U.S. C. ................................. ... 514/562; 514/474; 514/81 wherein R is hydrogen or an acyl group; R' is thiol or 58) Field of Search ................ 514/557, 562, 474,811 sulfonic group; and n is an integer of 1 or 2, (b) ascorbic (56) References Cited acid or a salt thereof and (c) a disulfide type thiamine derivative or a salt thereof. The composition is orally U.S. PATENT DOCUMENTS administered, preferably in the form of tablets. 2,283,817 5/1942 Martin et al. -
Drug Releasing Coatings for Medical Devices
(19) & (11) EP 2 500 046 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 19.09.2012 Bulletin 2012/38 A61L 29/16 (2006.01) A61L 31/16 (2006.01) (21) Application number: 11176688.7 (22) Date of filing: 16.05.2008 (84) Designated Contracting States: (72) Inventor: Wang, Lixiao AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Medina, MN Minnesota 55356 (US) HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR (74) Representative: HOFFMANN EITLE Designated Extension States: Patent- und Rechtsanwälte AL BA MK RS Arabellastrasse 4 81925 München (DE) (30) Priority: 19.10.2007 US 981380 P 19.10.2007 US 981384 P Remarks: 19.11.2007 US 942452 •This application was filed on 05-08-2011 as a divisional application to the application mentioned (62) Document number(s) of the earlier application(s) in under INID code 62. accordance with Art. 76 EPC: •Claims filed after the date of receipt of the divisional 08767783.7 / 2 073 860 application (Rule 68(4) EPC). (71) Applicant: Lutonix, Inc. Maple Grove, MN 55369 (US) (54) Drug releasing coatings for medical devices (57) The invention relates to a medical device for de- bonding, and a part that has an affinity to the therapeutic livering a therapeutic agent to a tissue. The medical de- agent by van der Waals interactions. In embodiments, vice has a layer overlying the exterior surface of the med- the additive is water- soluble. In further embodiments, the ical device. -
( 12 ) United States Patent
US009741942B2 (12 ) United States Patent (10 ) Patent No. : US 9 , 741, 942 B2 Stoessel et al. (45 ) Date of Patent: Aug . 22 , 2017 ( 54 ) MATERIALS FOR ORGANIC 11/ 02 ( 2013 .01 ) ; C09K 11/ 06 ( 2013 .01 ) ; HOIL ELECTROLUMINESCENT DEVICES 51/ 006 ( 2013 .01 ) ; HOIL 51/ 0052 ( 2013 .01 ) ; HOIL 51/ 0054 ( 2013 .01 ) ; HOIL 51 /0056 (71 ) Applicant : Merck Patent GmbH , Darmstadt (DE ) ( 2013 .01 ) ; HOIL 51 /0061 ( 2013 .01 ) ; HOIL ( 72 ) Inventors : Philipp Stoessel , Frankfurt am Main 51/ 0067 ( 2013 .01 ) ; HOIL 51/ 0071 ( 2013 .01 ) ; (DE ) ; Amir Hossain Parham , HOIL 51/ 0073 ( 2013 .01 ) ; HOIL 51 /0074 Frankfurt am Main (DE ) ; Christof ( 2013 .01 ) ; C09K 2211/ 1011 ( 2013 .01 ) ; COOK Pflumm , Darmstadt- Arheilgen (DE ) ; 2211/ 1029 ( 2013 . 01 ) ; CO9K 2211 / 1033 Anja Jatsch , Frankfurt am Main (DE ) ; ( 2013 .01 ) ; CO9K 2211/ 1037 ( 2013. 01 ) ; COOK Thomas Eberle , Landau (DE ) ; Jonas 2211 / 1059 ( 2013 . 01 ) ; C09K 2211 / 1088 Valentin Kroeber , Frankfurt am Main ( 2013 .01 ) ; COOK 2211 / 1092 ( 2013 . 01 ) ; HOIL 51 /0058 ( 2013 .01 ) ; HOIL 51 / 5008 ( 2013 . 01 ) ; (DE ) HOIL 51 /5012 (2013 . 01 ) ; HOIL 51/ 5056 ( 73 ) Assignee : Merck Patent GmbH , Darmstadt (DE ) ( 2013 . 01 ) ; HO1L 51 / 5072 ( 2013 .01 ) ; HOIL 51 /5092 (2013 .01 ) ; HOIL 51/ 5096 ( 2013 .01 ) ; ( * ) Notice : Subject to any disclaimer, the term of this HOIL 51 / 5221 ( 2013 .01 ) ; HOLL 2251/ 301 patent is extended or adjusted under 35 (2013 .01 ) ; HOIL 2251 /308 ( 2013 .01 ) U . S . C . 154 ( b ) by 305 days . (58 ) Field of Classification Search None (21 ) Appl. No. : 14 /434 , 460 See application file for complete search history . -
Derwent World Patents Index CPI Chemical Indexing User Guide © 2020 Clarivate
Derwent World Patents Index CPI Chemical Indexing User Guide © 2020 Clarivate First edition revision 1 published November 2000 Second edition published August 2020 ISBN: 0 901156 60 9 (Edition 1) ISBN: 1 903836 37 4 (Revised Edition 1) All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means – electronic, mechanical, recording, photocopying or otherwise – without express written permission from the copyright owner. Chemical Indexing User Guide Contents 1 Introduction to the User Guide ............................................................................. 1 2 Chemical Code Overview ................................................................................... 9 3 Searching With The Chemical Codes .................................................................. 13 4 How Derwent Indexes Patents ............................................................................ 25 5 Terms and Symbols Used in this User Guide ........................................................ 31 6 Elements Present ................................................................................................ 33 7 Ring Systems...................................................................................................... 65 8 Functional Groups ............................................................................................. 99 9 Part M: Miscellaneous Descriptors .................................................................... 167 10 Part N: Chemical -
(12) United States Patent (10) Patent No.: US 7.625,916 B2 Kawasugi (45) Date of Patent: Dec
US00762.5916B2 (12) United States Patent (10) Patent No.: US 7.625,916 B2 Kawasugi (45) Date of Patent: Dec. 1, 2009 (54) MEDICINAL COMPOSITION (56) References Cited (76) Inventor: Kaname Kawasugi, 26-10-405, U.S. PATENT DOCUMENTS Higashi-oi 5-chome, Shinagawa-ku 3,502,674. A 3/1970 Takamizawa et al. Tokyo (JP) 140-0011 4,687,777 A * 8/1987 Meguro et al. .............. 514,342 5,002.953 A * 3/1991 Hindley ......... ... 514,275 c - r 5,977.073 A * 1 1/1999 Khaled ........................ 514, 19 (*) Notice: Subject to any disclaimer, the term of this 6,166,219 A * 12/2000 Yamasaki et al. ........ 548/309.4 patent is extended or adjusted under 35 6.251926 B1* 6/2001 Momose et al. ............. 514,364 U.S.C. 154(b) by 122 days. 6,660,293 B2 * 12/2003 Giordano et al. ............ 424/439 (21) Appl. No.: 10/572,557 FOREIGN PATENT DOCUMENTS FR 2832O64 A1 * 5, 2003 (22) PCT Filed: Sep. 17, 2003 WO O2/O51441 T 2002 (86). PCT No.: PCT/UP03/11847 OTHER PUBLICATIONS Tamai, Hiroshi. “Diabetes and Vitamin Levels', Japanese Journal of S371 (c)(1), Clinical Medicine, vol. 57, No. 10, pp. 200-203, 1999. (2), (4) Date: Mar. 17, 2006 Hashizume, Naotaka, “Vitamin B1 Deficiency”. Igaku no Ayumi, vol. 198, No. 13, pp. 949-952, 2001. (87) PCT Pub. No.: WO2005/027967 * cited by examiner PCT Pub. Date: Mar. 31, 2005 Primary Examiner Kevin Weddington (74) Attorney, Agent, or Firm Oblon, Spivak, McClelland, Maier & Neustadt, L.L.P. (65) Prior Publication Data (57) ABSTRACT US 2007/O 10591.0 A1 May 10, 2007 A medicinal composition which comprises an insulin resis 51) Int. -
(5-Chloro-3-Methyl-1-(Pyridin-2-Yl) Pyrazolidin-4-Yl)-3- Substitutedphenylthiazolidin-4-Ones As Prospective Antimicrobial Agents
JOURNAL OF MODERN DRUG DISCOVERY AND DRUG DELIVERY RESEARCH Journal homepage: http://scienceq.org/Journals/JMDDR.php Research Article Open Access Synthesis of several 2-(5-chloro-3-methyl-1-(pyridin-2-yl) pyrazolidin-4-yl)-3- substitutedphenylthiazolidin-4-ones as prospective antimicrobial agents Ranjana Dubey1, Nidhi Chaudhary2 and Hament Panwar3* 1. Department of Chemistry, S.R.M. University, U.P., India. 2. Department of Chemistry, M.I.E.T., U.P, India. 3. Department of Chemistry, Neelkanth Institute of Technology, U.P, India. *Corresponding author: Hament Panwar Department of Chemistry, Neelkanth Institute of Technology, Modipuram-250110, Meerut, U.P, India. E-mail: [email protected] Received December 26, 2013; Accepted: December 28, 2013, Published: January 2, 2014. ABSTRACT Several 2-(5-chloro-3-methyl-1-(pyridin-2-yl) pyrazolidin-4-yl)-3- substitutedphenylthiazolidin-4-one (4a-f) have been synthesized by conventional synthesis methodology. The synthesized derivatives were characterized by IR, 1H-NMR, Mass and elemental analysis (C, H, N) . Furthermore the synthesized 2-(5-chloro-3-methyl-1-(pyridin-2-yl) pyrazolidin-4-yl)-3- substitutedphenylthiazolidin-4-one (4a-f) were tested for antimicrobial activities. The compound 4c displayed significant biological activities among the all tested derivatives. Keywords: Antibacterial, antifungal, thiazolidin-4-one, acute toxicity. INTRODUCTION Pyrazole symbolizes a class of simple aromatic ring RESULTS AND DISCUSSION organic compounds of the heterocyclic series which is a Chemistry 5-membered ring skeleton composed of three carbon and two Ethyl acetoacetate and 2-hydrazinylpyridine undergo nitrogen atoms. Ludwig Knorr was the first who coined the cyclo-condensation reaction to furnish 3-methyl- 1-phenyl- term pyrazole in 1883. -
Resource Recovery Through Thermochemical Conversion
Enhancing the circular economy: Resource recovery through thermochemical conversion processesll waste and biomass of land Doctoral Thesis in Materials Science and Engineering Enhancing the circular economy: Resource recovery through thermochemical conversion processes of land ll waste and biomass ILMAN NURAN ZAINI ISBN TRITAITMAVL : KTH www.kth.se Stockholm, Sweden Enhancing the circular economy: Resource recovery through thermochemical conversion processes of landfill waste and biomass ILMAN NURAN ZAINI Academic Dissertation which, with due permission of the KTH Royal Institute of Technology, is submitted for public defence for the Degree of Doctor of Technology on Friday the 11th June 2021, at 02:00 p.m. digital. Doctoral Thesis in Materials Science and Engineering KTH Royal Institute of Technology Stockholm, Sweden 2021 © Ilman Nuran Zaini ISBN 978-91-7873-913-4 TRITA-ITM-AVL 2021:29 Printed by: Universitetsservice US-AB, Sweden 2021 Abstract Currently, the global economy looses a considerable amount of potential secondary raw materials from the disposed waste streams. Furthermore, the existing landfill sites that often do not have proper environmental protection technologies pose a long-lasting risk for the environment, which urge immediate actions for landfill remediations. At the same time, the energy recovery from waste through conventional incinerators has been criticized for its CO2 emissions. Alternatively, pyrolysis and gasification offer the potential to recover secondary resources from waste and biomass streams, which can increase the circularity of the material resources and limit the CO2 emissions. This thesis aims to realize feasible thermochemical processes to enhance the material resources' circularity by treating landfill waste and biomass. Correspondingly, fundamental studies involving experimental works and process developments through lab-scale experiments and process simulations are carried out. -
(12) United States Patent (10) Patent No.: US 8,366,660 B2 Wang (45) Date of Patent: *Feb
US008366660B2 (12) United States Patent (10) Patent No.: US 8,366,660 B2 Wang (45) Date of Patent: *Feb. 5, 2013 (54) DRUG RELEASING COATINGS FOR 5,135,516 A 8/1992 Sahatian et al. MEDICAL DEVICES 5,138,051 A 8/1992 Hughes et al. 5,151,413 A 9, 1992 Caufield et al. 5,162.333 A 11/1992 Failli et al. (75) Inventor: Lixiao Wang, Medina, MN (US) 5,164,399 A 11/1992 Failli et al. 5,177,203 A 1/1993 Failli et al. (73) Assignee: Lutonix, Inc., New Hope, MN (US) 5,194,447 A 3, 1993 Kao 5,196,596 A 3/1993 Abatjoglou Notice: Subject to any disclaimer, the term of this 5, 199,951 A 4/1993 Spears (*) 5,221,670 A 6/1993 Caufield patent is extended or adjusted under 35 5,221,740 A 6/1993 Hughes U.S.C. 154(b) by 0 days. 5,233,036 A 8/1993 Hughes 5,252,579 A 10, 1993 Skotnicki et al. This patent is Subject to a terminal dis 5,254,089 A 10/1993 Wang et al. claimer. 5,260,300 A 11, 1993 Hu 5,262.423 A 11/1993 Kao (21) Appl. No.: 13/042.207 5,269,770 A 12/1993 Conway et al. 5,302.584 A 4, 1994 Kao et al. Filed: Mar. 7, 2011 5,304,121 A 4/1994 Sahatian (22) 5,324,261 A 6/1994 Amundson et al. 5,346,893 A 9, 1994 Failli et al. (65) Prior Publication Data 5,349,060 A 9, 1994 Kao et al. -
Pharmaceuticals and Medical Devices Safety Information No
Pharmaceuticals and Medical Devices Safety Information No. 215 July 2005 Table of Contents 1. Important Safety Information ································································ 2 .1. Ethionamide ······················································································ 2 .2. Etodolac ···························································································· 5 .3. Gemcitabine Hydrochloride ····························································· 10 .4. Omeprazole, Omeprazole Sodium ·················································· 12 2. Revision of PRECAUTIONS (No.167) Tiaprofenic Acid (and 17 others) ·································································· 16 3. List of products subject to Early Post-marketing Phase Vigilance ·············································· 23 This Pharmaceuticals and Medical Devices Safety Information (PMDSI) is issued based on safety information collected by the Ministry of Health, Labour and Welfare. It is intended to facilitate safer use of pharmaceuticals and medical devices by healthcare providers. PMDSI is available on the Pharmaceuticals and Medical Devices Agency website (http://www.pmda.go.jp/english/index.html) and on the MHLW website (http://www.mhlw.go.jp/, Japanese only). Published by Translated by Pharmaceutical and Food Safety Bureau, Pharmaceuticals and Medical Devices Agency Ministry of Health, Labour and Welfare Pharmaceutical and Food Safety Bureau, Office of Safety, Ministry of Health, Labour and Welfare Pharmaceuticals and Medical -
Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0 -
(12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.